NCT05740566 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 255
- group Id
- BG001
- value
- 254
- group Id
- BG002
- value
- 509
- units
- Participants
- groups
- description
- Participants were randomized to receive treatment according to the local SOC chemotherapy (lurbinectedin, topotecan, or amrubicin \[Japan only\]) in 21-day cycles.
- id
- BG000
- title
- Standard of Care (SOC)
- description
- Participants were randomized to receive tarlatamab as an IV infusion: A step dose of 1 mg on Cycle 1 Day 1 followed by the target dose 10 mg on Cycle 1 Day 8, Cycle 1 Day 15, and Q2W thereafter.
- id
- BG001
- title
- Tarlatamab 1 mg to 10 mg Q2W
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.2
- value
- 64.2
- group Id
- BG001
- spread
- 9.4
- value
- 63.6
- group Id
- BG002
- spread
- 9.3
- value
- 63.9
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 86
- group Id
- BG001
- value
- 72
- group Id
- BG002
- value
- 158
- title
- Female
- measurements
- group Id
- BG000
- value
- 169
- group Id
- BG001
- value
- 182
- group Id
- BG002
- value
- 351
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 23
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 128
- group Id
- BG001
- value
- 140
- group Id
- BG002
- value
- 268
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 116
- group Id
- BG001
- value
- 102
- group Id
- BG002
- value
- 218
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 107
- group Id
- BG001
- value
- 97
- group Id
- BG002
- value
- 204
- title
- Asian
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 5
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 139
- group Id
- BG001
- value
- 152
- group Id
- BG002
- value
- 291
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Other
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The intent-to-treat (ITT) analysis set included all randomized participants.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 255
- group Id
- BG001
- value
- 254
- group Id
- BG002
- value
- 509
- units
- Participants
- groups
- description
- Participants were randomized to receive treatment according to the local SOC chemotherapy (lurbinectedin, topotecan, or amrubicin \[Japan only\]) in 21-day cycles.
- id
- BG000
- title
- Standard of Care (SOC)
- description
- Participants were randomized to receive tarlatamab as an IV infusion: A step dose of 1 mg on Cycle 1 Day 1 followed by the target dose 10 mg on Cycle 1 Day 8, Cycle 1 Day 15, and Q2W thereafter.
- id
- BG001
- title
- Tarlatamab 1 mg to 10 mg Q2W
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.2
- value
- 64.2
- group Id
- BG001
- spread
- 9.4
- value
- 63.6
- group Id
- BG002
- spread
- 9.3
- value
- 63.9
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 86
- group Id
- BG001
- value
- 72
- group Id
- BG002
- value
- 158
- title
- Female
- measurements
- group Id
- BG000
- value
- 169
- group Id
- BG001
- value
- 182
- group Id
- BG002
- value
- 351
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 23
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 128
- group Id
- BG001
- value
- 140
- group Id
- BG002
- value
- 268
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 116
- group Id
- BG001
- value
- 102
- group Id
- BG002
- value
- 218
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 107
- group Id
- BG001
- value
- 97
- group Id
- BG002
- value
- 204
- title
- Asian
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 5
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 139
- group Id
- BG001
- value
- 152
- group Id
- BG002
- value
- 291
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- Other
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The intent-to-treat (ITT) analysis set included all randomized participants.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle